UTD1 plus capecitabine for HER2-negative breast cancer brain mets
Part of Brain & nervous system, Cancer clinical trials.
This trial tests whether adding a study drug called UTD1 to capecitabine can shrink or control breast cancer that has spread to the brain. It’s for people with HER2-negative metastatic breast cancer who have brain metastases and meet specific safety and lab requirements.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 to 70 years old
- Your breast cancer is HER2-negative (IHC or FISH test results confirm this)
- You have at least one brain metastasis spot seen on MRI that is big enough (at least 10 mm by the longest measurement)
- Your performance status is good (ECOG score 0 to 2, meaning you’re able to care for yourself and do light activities)
- Blood, liver, and kidney tests are within required safety ranges (including hemoglobin and white blood cell and neutrophil counts above set minimums)
- Your prior treatments fit the timing rules (no recent capecitabine in the last 6 months, and no recent major anti-cancer therapies that conflict with the study)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 study tests tucatinib plus T-DM1 (ado-trastuzumab emtansine) in people with HER2-positive metastatic solid tumors that have spread to the brain. It aims to shrink brain and body tumors and help control cancer that is progressing in the brain.
This trial tests a combination of a targeted cancer drug (T-DXd) with precise radiation to the brain for people with HER2-positive breast cancer that has spread to the brain. It aims to see if this combination can better control the brain tumors while being safe.
This trial tests a combination of two oral chemotherapy drugs (Utidelone and Capecitabine) for women with triple-negative breast cancer that did not fully disappear after standard chemo before surgery. The goal is to see if this treatment can lower the chance of the cancer coming back.
This trial tests if the combination of Utidelone and capecitabine can shrink brain metastases in people with HER2-negative breast cancer. It is designed for those whose cancer has spread to the brain and who have not had many prior treatments.
This trial tests a combination of two chemotherapy drugs (Utidelone and Capecitabine) for people with triple-negative breast cancer that has spread to the brain. The goal is to see if the combination can shrink or control the brain tumors.
This trial tests a combination of two anti-cancer drugs for people with HER2-positive breast cancer that has spread to the brain and has not responded to a prior antibody-drug conjugate treatment. The goal is to see if this combination can shrink or control brain metastases.
Hear when a new Metastatic HER2-Negative Breast Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.